News

Cigarettes account for slightly under half of smoking-related cancer deaths


 

FROM JAMA INTERNAL MEDICINE

References

Of the nearly 346,000 U.S. deaths caused by smoking-related cancers in 2011, about 48.5% were attributable to cigarette smoking, according to a research letter published online June 15 in JAMA Internal Medicine.

The latest data available for adults aged 35 years and older show that, of the 12 cancers determined to be caused by smoking, those most likely to be attributed to cigarette smoking were cancers of the lung, bronchus, and trachea (80.2%) and the larynx (76.6%). Lung cancers were, by far, the most numerous, representing 126,000 of the nearly 168,000 total smoking-attributable cancers, said Rebecca L. Siegel of the American Cancer Society, Atlanta, and her associates.

The next most numerous smoking-attributable cancer was that of the esophagus, with a total of 7,300 deaths in 2011, they reported (JAMA Intern. Med. 2015 June 15 [doi:10.1001/jamainternmed.2015.2398]).

The investigators suggested that the “generally lower proportions of deaths caused by smoking in 2011 than in 2000 to 2004” may be the result of a drop in the prevalence of smoking from 23.2% in 2000 to 18.1% in 2012.

Data for the study came from the National Health Interview Survey, the Cancer Prevention Study II, and a pooled contemporary cohort (a group of five studies). Statistical methods and data sources match those used in smoking-attributable mortality calculations in the 2014 surgeon general’s report on smoking.

Analysis of the data was funded by the American Cancer Society. Four of the seven researchers are employees of the ACS.

rfranki@frontlinemedcom.com

Recommended Reading

New agent targets EGFR resistance in NSCLC
MDedge Hematology and Oncology
ELCC: Urine tumor DNA shows high testing promise
MDedge Hematology and Oncology
Statin use associated with reduced lung cancer mortality
MDedge Hematology and Oncology
Health professionals’ attitudes toward the detection and management of cancer-related anorexia-cachexia syndrome, and a proposal for standardized assessment
MDedge Hematology and Oncology
VIDEO: Level of e-cigarette power contributes to potentially hazardous effects
MDedge Hematology and Oncology
ELCC: Survey reveals worldwide underuse of EGFR-mutation testing
MDedge Hematology and Oncology
Bevacizumab beneficial for Chinese NSCLC patients
MDedge Hematology and Oncology
AATS: No postpneumonectomy survival benefit in adding radiation to chemotherapy for NSCLC
MDedge Hematology and Oncology
Nivolumab transforms practice for advanced, refractory nonsquamous NSCLC
MDedge Hematology and Oncology
ASCO: Precision medicine initiatives take wing
MDedge Hematology and Oncology